Reference Ranges vs Risk Thresholds in Ageing Biomarkers

Key Takeaways

Reference ranges describe what is common in a selected population, while risk thresholds are set because outcomes worsen above or below a chosen point.
A value can sit inside a population reference range and still be associated with higher long-term risk.
Many ageing biomarkers are interpreted better through gradients of risk, trajectories, or context-specific cut-points than through a simple normal-versus-abnormal frame.
This distinction matters because biological age tools, gait speed, grip strength, and blood biomarkers are not all validated in the same way.

Who This Is Useful For

This page is useful for readers trying to interpret biomarker reports that present a result as "normal," "out of range," or "high risk." It is especially relevant for people comparing routine lab ranges with ageing biomarkers, functional measures, or biological age scores that are often linked to future outcomes rather than to a single healthy reference interval. [1] [4] [5]

Reference Ranges

A reference range usually describes the distribution of values seen in an apparently healthy reference population, often using the central 95% of results. That makes it a population-description tool, not a direct statement about future risk. The range depends on who was sampled, how health was defined, and whether the interval was partitioned by age, sex, or other characteristics. [1] [2] [3]

Risk Thresholds

A risk threshold is different. It is set because a value above or below that point is associated with a clinically important change in probability of an outcome, such as disability, disease, or mortality. In laboratory medicine these are often called decision limits or clinical decision thresholds. They are outcome-oriented rather than purely distribution-oriented. [1] [3]

Why the Distinction Matters in Ageing Biomarkers

Ageing biomarkers are often evaluated by whether they predict mortality, functional decline, morbidity, or response to intervention better than chronological age alone. That means their value frequently lies in risk stratification or longitudinal tracking, not in showing whether someone falls inside a population "normal range." Reviews and consensus statements in geroscience emphasize context of use, predictive validity, and responsiveness rather than a single universal cut-off. [4] [5] [6]

Reference Ranges vs Risk Thresholds at a Glance

Dimension	Reference Range	Risk Threshold	Why It Matters
Main question	What values are typical in a selected reference population?	At what point does outcome risk become meaningfully different?	Typical is not the same as low-risk
How it is derived	Usually from the distribution of values in people labeled healthy	Usually from associations with diagnosis, prognosis, or treatment benefit	Distribution-based and outcome-based methods answer different questions
Interpretation style	Inside or outside range	Lower or higher probability of adverse outcomes	Risk can change gradually even without crossing a "normal" boundary
Common ageing examples	Age- and sex-specific distributions for some lab measures	Slow gait speed, low grip strength, or age-acceleration signals associated with poorer outcomes	Many ageing measures are more useful as risk markers than as normal-range tests
Main limitation	Can normalize common but unhealthy values	Depends on outcome choice, cohort, and intended use	Neither framework is automatically universal

Why "Normal for Age" Can Still Mean Higher Risk

A marker can drift with age in a way that is statistically common without becoming biologically benign. Laboratory medicine has long recognized this problem: common population values and clinically useful decision limits can diverge substantially. Cholesterol is a classic example, where historically common values did not necessarily correspond to lower cardiovascular risk. [1] [3]

The same logic applies to ageing research. If a biomarker becomes less favorable with age across much of the population, a broad age-specific reference distribution may describe what is common while still failing to identify the part of the distribution associated with steeper functional decline or earlier death. [4] [5]

Functional Biomarkers Often Use Outcome-Based Cut-Points

Functional ageing biomarkers illustrate the difference clearly. Gait speed is not usually interpreted by asking whether a person falls inside a broad "normal" population interval. Instead, studies examine how progressively slower walking speed relates to disability and survival, and commonly used cut-points such as around 0.8 m/s are tied to prognosis rather than to a purely descriptive reference range. [6] [7]

Grip strength is similar. Consensus cut-points for low strength were developed to identify probable sarcopenia or frailty-related risk, not simply to mark the edge of a population distribution in healthy adults. Those thresholds are therefore closer to risk thresholds than to neutral reference ranges. [6] [8]

Biological Age Scores Usually Reflect Gradients, Not Hard Clinical Boundaries

Epigenetic clocks and other composite ageing biomarkers are generally validated through associations with chronological age, mortality, disease, disability, or intervention response. In most cases there is no universally accepted clinical threshold that cleanly separates safe from unsafe states across populations. Their outputs are better understood as probabilistic or comparative signals than as diagnostic boundaries. [4] [5] [9]

Evidence Quality and Interpretation

Confidence is strong that reference ranges and risk thresholds are not interchangeable concepts. This distinction is well established in laboratory medicine methodology. [1] [2] [3]

Confidence is also strong that many ageing biomarkers are evaluated primarily for prediction, responsiveness, or stratification rather than for fit to a single healthy reference interval. [4] [5] [6]

Confidence is moderate that specific thresholds can still be useful in some ageing contexts, especially for functional measures such as gait speed or grip strength, but those cut-points remain dependent on outcome definition, cohort, and use case. [7] [8]

Confidence is strong that current biological age clocks do not yet justify simple clinical normal-versus-abnormal interpretation for individuals. [5] [9]

What This Does Not Mean

It does not mean reference ranges are useless; they remain important descriptive tools for many tests.
It does not mean every ageing biomarker already has a validated risk threshold.
It does not mean one threshold applies equally across ages, populations, and clinical contexts.
It does not mean a continuous biomarker becomes meaningless just because it lacks a hard boundary.

Practical Interpretation Examples

If a blood marker is inside a laboratory reference range: that does not automatically mean the value is optimized for long-term ageing-related risk. [1] [3]
If gait speed is below a commonly used cut-point: that usually reflects higher outcome risk, not just deviation from what is statistically common. [7]
If an epigenetic clock score is "older" than chronological age: that is usually a comparative risk signal derived from group-level data, not a definitive clinical diagnosis. [5] [9]

Summary

Reference ranges tell you what is common in a chosen population. Risk thresholds try to identify where outcomes meaningfully change. In ageing biomarker research, that second question is often the more important one, which is why functional measures and biological age tools are often interpreted through prediction, calibration, and longitudinal change rather than through a simple normal-range model. [1] [4] [5]

References

Ozarda, Y., Sikaris, K., Streichert, T., & Macri, J. (2018). Distinguishing reference intervals and clinical decision limits: A review by the IFCC Committee on Reference Intervals and Decision Limits. Critical Reviews in Clinical Laboratory Sciences, 55(6), 420-431. https://pubmed.ncbi.nlm.nih.gov/30047297/
Miller, W. G., Horowitz, G. L., Ceriotti, F., Fleming, J. K., Greenberg, N., Katayev, A., et al. (2016). Reference intervals: strengths, weaknesses, and challenges. Clinical Chemistry, 62(7), 916-923. https://academic.oup.com/clinchem/article/62/7/916/5611870
Horowitz, G. L. (2008). Reference intervals: practical aspects. eJIFCC, 19(2), 95-105. https://pmc.ncbi.nlm.nih.gov/articles/PMC4975204/
Biomarkers of Aging Consortium, Moqri, M., Herzog, C., Poganik, J. R., et al. (2023). Biomarkers of aging for the identification and evaluation of longevity interventions. Cell, 186(18), 3758-3775. https://pmc.ncbi.nlm.nih.gov/articles/PMC11088934/
Moqri, M., Herzog, C., Poganik, J. R., et al. (2024). Validation of biomarkers of aging. Nature Medicine, 30(2), 360-372. https://www.nature.com/articles/s41591-023-02784-9
Perri, G., Poganik, J. R., Levine, M. E., et al. (2025). An expert consensus statement on biomarkers of aging for use in intervention studies. Journal of Gerontology: Biological Sciences, 80(5), glae297. https://academic.oup.com/biomedgerontology/article/80/5/glae297/7930267
Studenski, S., Perera, S., Patel, K., et al. (2011). Gait speed and survival in older adults. JAMA, 305(1), 50-58. https://pmc.ncbi.nlm.nih.gov/articles/PMC3080184/
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., et al. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16-31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6322506/
Apsley, A. T., Etzel, L., Ye, Q., & Shalev, I. (2025). From population science to the clinic? Limits of epigenetic clocks as personal biomarkers. Epigenomics, 17(18), 1447-1461. https://pmc.ncbi.nlm.nih.gov/articles/PMC12714307/

Educational Disclaimer

This content is provided for educational purposes only and does not constitute medical advice.